Providing a diverse range of perspectives from bullish to bearish, 16 analysts have published ratings on Vertex Pharmaceuticals VRTX in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 9 | 5 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 2 | 1 | 0 | 0 |
| 2M Ago | 0 | 2 | 1 | 0 | 0 |
| 3M Ago | 1 | 4 | 3 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $383.0, a high estimate of $415.00, and a low estimate of $347.00. Surpassing the previous average price target of $370.33, the current average has increased by 3.42%.
Decoding Analyst Ratings: A Detailed Look
The standing of Vertex Pharmaceuticals among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Olivia Brayer | Cantor Fitzgerald | Maintains | Overweight | $415.00 | - |
| Olivia Brayer | Cantor Fitzgerald | Maintains | Overweight | $380.00 | - |
| Brian Abrahams | RBC Capital | Raises | Sector Perform | $379.00 | $347.00 |
| Gena Wang | Barclays | Raises | Overweight | $415.00 | $408.00 |
| Andrew Fein | HC Wainwright & Co. | Raises | Buy | $397.00 | $390.00 |
| Olivia Brayer | Cantor Fitzgerald | Maintains | Overweight | $380.00 | - |
| Paul Matteis | Stifel | Maintains | Hold | $373.00 | - |
| Olivia Brayer | Cantor Fitzgerald | Maintains | Overweight | $380.00 | - |
| Matthew Harrison | Morgan Stanley | Raises | Equal-Weight | $364.00 | $359.00 |
| Brian Abrahams | RBC Capital | Lowers | Sector Perform | $347.00 | $350.00 |
| Evan Seigerman | BMO Capital | Raises | Outperform | $415.00 | $389.00 |
| Olivia Brayer | Cantor Fitzgerald | Raises | Overweight | $380.00 | $370.00 |
| Paul Matteis | Stifel | Raises | Hold | $373.00 | $340.00 |
| Andrew Fein | HC Wainwright & Co. | Raises | Buy | $390.00 | $380.00 |
| Eric Schmidt | Cantor Fitzgerald | Maintains | Overweight | $370.00 | - |
| Olivia Brayer | Cantor Fitzgerald | Maintains | Overweight | $370.00 | - |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Vertex Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Vertex Pharmaceuticals compared to the broader market.
- Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.
To gain a panoramic view of Vertex Pharmaceuticals's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Vertex Pharmaceuticals analyst ratings.
Get to Know Vertex Pharmaceuticals Better
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
A Deep Dive into Vertex Pharmaceuticals's Financials
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Vertex Pharmaceuticals's remarkable performance in 3 months is evident. As of 30 September, 2023, the company achieved an impressive revenue growth rate of 6.39%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Vertex Pharmaceuticals's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 41.69% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Vertex Pharmaceuticals's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.47% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Vertex Pharmaceuticals's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.92% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.05.
The Basics of Analyst Ratings
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
